生物活性 | Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation[1][2][3][4][5][6][7]. | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
| ||||||||||||
体外研究 (In Vitro) | Y-27632 抑制 ROCK 激酶家族比其他激酶 (包括蛋白激酶 C、cAMP 依赖性激酶和肌球蛋白轻链激酶) 强 100 倍。Y-27632 以浓度依赖性方式延长滞后时间并延迟 BrdU 标记细胞的出现,在用 10 和 100 μM Y-27632 处理的 Swiss 3T3 细胞中分别观察到约 1 和 4 小时的延迟[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||
体内研究 (In Vivo) | 与盐水组相比,Y-27632 (5 和 10 mg/kg) 显著延长肌阵挛发作的发作时间。与生理盐水组相比,Y-27632 (5 和 10 mg/kg) 可显著延长阵挛性惊厥的发作时间[3]。与对照动物 (SS 组) 相比,用二甲基亚硝胺 (DMN) 处理会导致大鼠体重和肝脏重量 (DMN-S 组) 显著降低。口服 Y27632 (30 mg/kg) 从根本上防止这种 DMN 诱导的大鼠身体和肝脏体重减轻 (DMN-Y 组)[4]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||
分子量 | 247.34 | ||||||||||||
Formula | C14H21N3O | ||||||||||||
CAS 号 | 146986-50-7 | ||||||||||||
性状 | 固体 | ||||||||||||
颜色 | White to off-white | ||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||
储存方式 | -20°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) | ||||||||||||
溶解性数据 | 细胞实验: DMSO 中的溶解度 : 25 mg/mL (101.08 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO) 配制储备液
查看完整储备液配制表 * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 动物实验: 请根据您的 实验动物和给药方式 选择适当的溶解方案。 以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
以下溶解方案,请直接配制工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。
动物溶解方案计算器 请输入动物实验的基本信息: 给药剂量 mg/kg 动物的平均体重 g 每只动物的给药体积 μL 动物数量 只 由于实验过程有损耗,建议您多配一只动物的量 请输入您的动物体内配方组成: % DMSO + % + % Tween-80 + % Saline 如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。 方案所需 助溶剂 包括:DMSO, ,均可在 MCE 网站选购。 ,Tween 80,均可在 MCE 网站选购。 计算结果 工作液所需浓度 : mg/mL 储备液配制方法 : mg 药物溶于 μL DMSO(母液浓度为 mg/mL)。 *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) 您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。 动物实验体内工作液的配制方法 :取 μLDMSO储备液,加入 μL。 μL,混合均匀至澄清,再加 μLTween 80,混合均匀至澄清,再加 μL生理盐水。 连续给药周期超过半月以上,请谨慎选择该方案。 请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。 | ||||||||||||
纯度 & 产品资料 | 纯度: 99.91%
COA (259 KB) HNMR (252 KB) RP-HPLC (252 KB) MS (69 KB) 产品使用指南 (1538 KB) | ||||||||||||
参考文献 |
|
Kinase Assay [1] | Recombinant ROCK-I, ROCK-II, PKN, or citron kinase is expressed in HeLa cells as Myc-tagged proteins by transfection using Lipofectamine, and is precipitated from the cell lysates by the use of 9E10 monoclonal anti-Myc antibody coupled to G protein-Sepharose. Recovered immunocomplexes are incubated with various concentrations of [32P]ATP and 10 mg of histone type 2 as substrates in the absence or presence of various concentrations of either Y-27632 or Y-30141 at 30°C for 30 min in a total volume of 30 μL of the kinase buffer containing 50 mM HEPES-NaOH, pH 7.4, 10 mM MgCl2, 5 mM MnCl2, 0.02% Briji 35, and 2 mM dithiothreitol. PKCa is incubated with 5 μM [32P]ATP and 200 μg/mL histone type 2 as substrates in the absence or presence of various concentrations of either Y-27632 or Y-30141 at 30°C for 10 min in a kinase buffer containing 50 mM Tris-HCl, pH 7.5, 0.5 mM CaCl2, 5 mM magnesium acetate, 25 μg/mL phosphatidyl serine, 50 ng/mL 12-O-tetradecanoylphorbol-13-acetate and 0.001% leupeptin in a total volume of 30 μL. Incubation is terminated by the addition of 10 μL of 43 Laemmli sample buffer. After boiling for 5 min, the mixture is subjected to SDS-polyacrylamide gel electrophoresis on a 16% gel. The gel is stained with Coomassie Brilliant Blue, and then dried. The bands corresponding to histone type 2 are excised, and the radioactivity is measured[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Cell Assay [1] | HeLa cells are plated at a density of 3×104 cells per 3.5-cm dish. The cells are cultured in DMEM containing 10% FBS in the presence of 10 mM Thymidine for 16 h. After the cells are washed with DMEM containing 10% FBS, they are cultured for an additional 8 h, and then 40 ng/mL of Nocodazole is added. After 11.5 h of the Nocodazole treatment, various concentrations of Y-27632 (0-300 μM), Y-30141, or vehicle is added and the cells are incubated for another 30 min[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
Animal Administration [3][4] | Mice[3] MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
-
[1]. Ishizaki T, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83.
[2]. Xue ZW, et al. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells.Chin Med J (Engl). 2012 Sep;125(18):3332-5.
[3]. Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34(4):529-36.
[4]. Inan S, et al. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155(1):44-51.
[5]. Maldonado M, et al. ROCK inhibitor primes human induced pluripotent stem cells to selectively differentiate towardsmesendodermal lineage via epithelial-mesenchymal transition-like modulation. Stem Cell Res. 2016 Sep;17(2):222-227.
[6]. Kan L, et al. Rho-Associated Kinase Inhibitor (Y-27632) Attenuates Doxorubicin-Induced Apoptosis of Human Cardiac Stem Cells. PLoS One. 2015;10(12):e0144513. Published 2015 Dec 8.
[7]. Zhang L, et al. ROCK inhibitor Y-27632 suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells and increases their cloning efficiency. PLoS One. 2011;6(3):e18271. Published 2011 Mar 28.
[8]. Svoboda KK, et al. ROCK inhibitor (Y27632) increases apoptosis and disrupts the actin cortical mat in embryonic avian corneal epithelium. Dev Dyn. 2004;229(3):579-590.
Y-27632 相关分类
- Cancer
- 肿瘤靶向治疗 肿瘤干细胞 肿瘤代谢与转移
- Cell Cycle/DNA Damage Stem Cell/Wnt Cytoskeleton TGF-beta/Smad Apoptosis
- Organoid ROCK Apoptosis
完整储备液配制表
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。
可选溶剂 | 浓度 溶剂体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 4.0430 mL | 20.2151 mL | 40.4302 mL | 101.0754 mL |
5 mM | 0.8086 mL | 4.0430 mL | 8.0860 mL | 20.2151 mL | |
10 mM | 0.4043 mL | 2.0215 mL | 4.0430 mL | 10.1075 mL | |
15 mM | 0.2695 mL | 1.3477 mL | 2.6953 mL | 6.7384 mL | |
20 mM | 0.2022 mL | 1.0108 mL | 2.0215 mL | 5.0538 mL | |
25 mM | 0.1617 mL | 0.8086 mL | 1.6172 mL | 4.0430 mL | |
30 mM | 0.1348 mL | 0.6738 mL | 1.3477 mL | 3.3692 mL | |
40 mM | 0.1011 mL | 0.5054 mL | 1.0108 mL | 2.5269 mL | |
50 mM | 0.0809 mL | 0.4043 mL | 0.8086 mL | 2.0215 mL | |
60 mM | 0.0674 mL | 0.3369 mL | 0.6738 mL | 1.6846 mL | |
80 mM | 0.0505 mL | 0.2527 mL | 0.5054 mL | 1.2634 mL | |
100 mM | 0.0404 mL | 0.2022 mL | 0.4043 mL | 1.0108 mL |
Help & FAQs
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Keywords:
Y-27632146986-50-7Y27632Y 27632OrganoidROCKApoptosisRho-associated protein kinaseRho-associated kinaseRho-kinaseROKInhibitorinhibitorinhibit